Skip to main content

BIOMEDICAL ADVANCED RESEARCH
AND DEVELOPMENT AUTHORITY (BARDA)

Subscribe to RSS: RSS

The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.

The mission of the Biomedical Advanced Research and Development Authority (BARDA) is to develop and procure medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. Specifically, BARDA supports the advanced development and procurement of drugs, vaccines and other products that are considered priorities for national health security through its programmatic initiatives.

[+] CORE SERVICES

[+] CBRN PROGRAMS

[+] PANDEMIC INFLUENZA

[+] INNOVATION

[+] STOCKPILE BUILDING

BARDA funding and acquisitions bridge the "valley of death" characterizing the late stages of product development. BARDA's support ensures continuity of funding for medical countermeasures developed by industry or emerging from the basic research and preclinical development activities sponsored by the National Institutes of Health (NIH). In procuring medical countermeasures for the Strategic National Stockpile, BARDA enhances the capabilities of the Centers for Disease Control and Prevention (CDC) to organize an effective response.

BARDA manages Project BioShield, which includes the procurement and advanced development of medical countermeasures for chemical, biological, radiological, and nuclear agents, as well as the advanced development and procurement of medical countermeasures for pandemic influenza and other emerging infectious diseases that fall outside the auspices of Project BioShield. In addition, BARDA manages the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and is a key partner in implementing the PHEMCE strategies.

To learn more about requirements setting for medical countermeasure research and development click here.

Publications

 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan 2015

Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan 2015

The United States (U.S.) continues to face a range of serious threats to its national health security from the deliberate use or accidental release of chemical, biological, radiological, and nuclear (CBRN) agents, as well as from naturally occurring and emerging infectious diseases (EID), including pandemic influenza....
Project Bioshield

Project BioShield Report 2014

Significant progress was made in 2014 in the regulatory review and approval of MCMs procured under Project BioShield......
Project Bioshield

Project BioShield Annual Report to Congress 2012

The Medical Countermeasures (MCM) Enterprise had a significant year in 2012. The U.S. Department of Health and Human Services' (HHS) continued to leverage...

view all publications

BARDA Project Listing

View maps and project details for BARDA projects with work performed inside and outside of the United States.

Industry partners are encouraged to visit the BARDA BAA and sign up for a TechWatch meeting.


The PHEMCE has taken a holistic, end-to-end approach to planning that considers multiple aspects of the medical countermeasures mission. The HHS PHEMCE Strategy for Chemical, Biological, Radiological, and Nuclear (CBRN) Threats establishes the goals and objectives that HHS will use to ensure that medical countermeasures are available for effective use against the highest priority CBRN threats facing the Nation. The HHS PHEMCE Implementation Plan for CBRN Threats is a prioritized plan with near-, mid-, and long-term goals for research, development, and acquisition of medical countermeasures.

The PHEMCE is led by the Enterprise Senior Council (ESC), which serves as the decision forum for MCM development policy and implementation. The ESC is chaired by ASPR and is comprised of Senior Leaders of the enterprise.